Ameriprise’s PTC Therapeutics PTCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $14M | Buy |
171,874
+5,215
| +3% | +$377K | ﹤0.01% | 1788 |
|
|
2026
Q1 | $11.4M | Buy |
166,659
+19,075
| +13% | +$1.35M | ﹤0.01% | 1830 |
|
|
2025
Q4 | $11.2M | Buy |
147,584
+136,954
| +1,288% | +$9.95M | ﹤0.01% | 1821 |
|
|
2025
Q3 | $652K | Hold |
10,630
| – | – | ﹤0.01% | 3535 |
|
|
2025
Q2 | $519K | Sell |
10,630
-7,533
| -41% | -$358K | ﹤0.01% | 3519 |
|
|
2025
Q1 | $926K | Sell |
18,163
-24,771
| -58% | -$1.24M | ﹤0.01% | 3241 |
|
|
2024
Q4 | $1.94M | Sell |
42,934
-26,126
| -38% | -$1.12M | ﹤0.01% | 2944 |
|
|
2024
Q3 | $2.56M | Sell |
69,060
-9,792
| -12% | -$328K | ﹤0.01% | 2776 |
|
|
2024
Q2 | $2.41M | Buy |
78,852
+5,201
| +7% | +$168K | ﹤0.01% | 2784 |
|
|
2024
Q1 | $2.14M | Buy |
73,651
+153
| +0.2% | +$4.29K | ﹤0.01% | 2833 |
|
|
2023
Q4 | $2.03M | Sell |
73,498
-562,280
| -88% | -$12.9M | ﹤0.01% | 2865 |
|
|
2023
Q3 | $14.2M | Buy |
635,778
+234,592
| +58% | +$8.72M | ﹤0.01% | 1445 |
|
|
2023
Q2 | $16.3M | Buy |
401,186
+320,131
| +395% | +$15.7M | 0.01% | 1394 |
|
|
2023
Q1 | $3.93M | Buy |
81,055
+29,111
| +56% | +$1.33M | ﹤0.01% | 2478 |
|
|
2022
Q4 | $1.98M | Buy |
51,944
+34,476
| +197% | +$1.43M | ﹤0.01% | 2814 |
|
|
2022
Q3 | $876K | Sell |
17,468
-321
| -2% | -$15.7K | ﹤0.01% | 3177 |
|
|
2022
Q2 | $713K | Sell |
17,789
-229
| -1% | -$8.03K | ﹤0.01% | 3259 |
|
|
2022
Q1 | $672K | Buy |
+18,018
| New | +$694K | ﹤0.01% | 3370 |
|
|
2021
Q2 | – | Sell |
-11,807
| Closed | -$559K | – | 3952 |
|
|
2021
Q1 | $559K | Sell |
11,807
-15,805
| -57% | -$939K | ﹤0.01% | 3359 |
|
|
2020
Q4 | $1.69M | Sell |
27,612
-13,828
| -33% | -$815K | ﹤0.01% | 2871 |
|
|
2020
Q3 | $1.94M | Sell |
41,440
-16,550
| -29% | -$815K | ﹤0.01% | 2687 |
|
|
2020
Q2 | $2.94M | Buy |
57,990
+6,145
| +12% | +$302K | ﹤0.01% | 2408 |
|
|
2020
Q1 | $2.31M | Buy |
51,845
+11,270
| +28% | +$567K | ﹤0.01% | 2401 |
|
|
2019
Q4 | $1.95M | Buy |
40,575
+544
| +1% | +$23.1K | ﹤0.01% | 2741 |
|
|
2019
Q3 | $1.35M | Sell |
40,031
-8,980
| -18% | -$391K | ﹤0.01% | 2878 |
|
|
2019
Q2 | $2.21M | Sell |
49,011
-49,915
| -50% | -$1.97M | ﹤0.01% | 2688 |
|
|
2019
Q1 | $3.72M | Sell |
98,926
-1,333
| -1% | -$44.8K | ﹤0.01% | 2412 |
|
|
2018
Q4 | $3.44M | Buy |
+100,259
| New | +$3.6M | ﹤0.01% | 2366 |
|
|
2018
Q3 | – | Sell |
-25,724
| Closed | -$867K | – | 3767 |
|
|
2018
Q2 | $867K | Buy |
25,724
+312
| +1% | +$9.73K | ﹤0.01% | 3068 |
|
|
2018
Q1 | $688K | Sell |
25,412
-584
| -2% | -$14.8K | ﹤0.01% | 3114 |
|
|
2017
Q4 | $434K | Sell |
25,996
-53,965
| -67% | -$913K | ﹤0.01% | 3255 |
|
|
2017
Q3 | $1.6M | Sell |
79,961
-361,512
| -82% | -$7.08M | ﹤0.01% | 2721 |
|
|
2017
Q2 | $8.09M | Sell |
441,473
-212,428
| -32% | -$2.86M | ﹤0.01% | 1729 |
|
|
2017
Q1 | $6.43M | Buy |
653,901
+394,878
| +152% | +$4.78M | ﹤0.01% | 1848 |
|
|
2016
Q4 | $2.83M | Sell |
259,023
-208,596
| -45% | -$2.19M | ﹤0.01% | 2452 |
|
|
2016
Q3 | $6.55M | Buy |
467,619
+68,451
| +17% | +$556K | ﹤0.01% | 1787 |
|
|
2016
Q2 | $2.8M | Buy |
399,168
+67,925
| +21% | +$498K | ﹤0.01% | 2341 |
|
|
2016
Q1 | $2.13M | Buy |
331,243
+263,811
| +391% | +$4.58M | ﹤0.01% | 2480 |
|
|
2015
Q4 | $2.19M | Sell |
67,432
-13,262
| -16% | -$390K | ﹤0.01% | 2551 |
|
|
2015
Q3 | $2.15M | Sell |
80,694
-9,790
| -11% | -$419K | ﹤0.01% | 2572 |
|
|
2015
Q2 | $4.35M | Buy |
90,484
+18,667
| +26% | +$1.09M | ﹤0.01% | 2238 |
|
|
2015
Q1 | $4.37M | Buy |
71,817
+16,005
| +29% | +$977K | ﹤0.01% | 2181 |
|
|
2014
Q4 | $2.89M | Buy |
55,812
+21,370
| +62% | +$941K | ﹤0.01% | 2374 |
|
|
2014
Q3 | $1.52M | Sell |
34,442
-27,315
| -44% | -$855K | ﹤0.01% | 2622 |
|
|
2014
Q2 | $1.61M | Buy |
+61,757
| New | +$1.32M | ﹤0.01% | 2608 |
|
Other funds holding PTCT
RI
JT
Ameriprise's PTCT Position: Q2 2026 in Review
Ameriprise increased its PTC Therapeutics (PTCT) stake by 3.1% in Q2 2026, buying an estimated $377K and bringing the position to 171,874 shares worth $14M. The position accounts for ﹤0.01% of the portfolio, ranked #1788.
Ameriprise first reported a position in PTCT in Q2 2014 and has held it in 45 quarters since. The position peaked at $16.3M in Q2 2023. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.
- Ameriprise held 171,874 shares of PTC Therapeutics worth $14M as of Q2 2026.
- Ameriprise bought 5,215 PTC Therapeutics shares in Q2 2026, an estimated $377K.
- PTC Therapeutics made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #1788 holding.
- Ameriprise first reported a position in PTC Therapeutics in Q2 2014 and has held it in 45 quarters since.
- Ameriprise's PTC Therapeutics position peaked at $16.3M in Q2 2023.
- 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.
Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.